Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $16.00 to $14.00. They now have an "outperform" rating on the stock.
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
Sanofi to make €1bn biomanufacturing investment in France [Yahoo! Finance]
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely? [Yahoo! Finance]
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $15.00 price target on the stock.